Form 13-F position report

TRAVERE THERAPEUTICS INC

Reported by ORBIMED ADVISORS LLC

TVTX CUSIP 89422G107 Manager CIK 0001055951

Reported 1,200,425 shares, up 947,425 (374.5%) from the prior quarter.

Reported value 391.8%; share count 374.5% vs. the prior quarter.

Added
% of reported 13F value 1.29% This manager · Q3 2026
Shares 1,200,425 Quarter-end amount reported
Reported value $70,681,024 Fair value at quarter end
Consecutive quarters held 2 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-06-30 18710000
2022-09-30 30877000
2022-12-31 26353324
2023-03-31 39229307
2023-06-30 32534016
2023-09-30 0
2026-06-30 14372930
2026-09-30 70681024

Quarterly position history

How this manager's reported quarter-end position changed over time.

8 quarters
Quarterly reported position history for TRAVERE THERAPEUTICS INC held by ORBIMED ADVISORS LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 1,200,425 +947,425 (374.5%) 1.29% $70,681,024 2026-11-16
Q2 2026 New 253,000 +253,000 (0.0%) 0.27% $14,372,930 2026-08-14
Q3 2023 Reduced 0 -2,118,100 (-100.0%) 0 $0 2023-11-14
Q2 2023 Added 2,118,100 +373,800 (21.4%) 0.6% $32,534,016 2023-08-14
Q1 2023 Added 1,744,300 +491,170 (39.2%) 0.78% $39,229,307 2023-05-15
Q4 2022 Unchanged 1,253,130 0 (0.0%) 0.51% $26,353,324 2023-02-14
Q3 2022 Added 1,253,130 +480,930 (62.3%) 0.58% $30,877,000 2022-11-14
Q2 2022 New 772,200 +772,200 (0.0%) 0.34% $18,710,000 2022-08-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

377 managers reported TRAVERE THERAPEUTICS INC for Q3 2026.

Managers reporting TRAVERE THERAPEUTICS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
JANUS HENDERSON GROUP PLC Added 11,891,480 +471,894 0.3% $700,058,180 1 qtr
BlackRock Inc Added 8,673,231 +652,568 < 0.01% $510,679,819 9 qtrs
FMR LLC Reduced 5,867,919 -1,228,695 0.01% $345,503,077 24 qtrs
Bank of America Corporation Added 5,824,254 +1,255,913 0.02% $342,932,099 24 qtrs
STATE STREET CORPORATION Added 4,387,309 +131,085 < 0.01% $258,324,754 23 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 4,192,887 +84,193 < 0.01% $246,877,187 3 qtrs
PERCEPTIVE ADVISORS LLC Reduced 3,542,913 -209,661 3.63% $208,606,717 6 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Added 3,040,158 +1,498,541 < 0.01% $179,004,503 3 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 2,420,340 +48,453 < 0.01% $142,537,650 24 qtrs
ADAGE CAPITAL PARTNERS GP L L C Reduced 2,410,485 -158,871 0.2% $141,929,357 12 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
292,100
Shared
0
None
908,325

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.